December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Jordi Remon: Alectinib vs crizotinib in 1st line in Asian patients with ALK+ NSCLC
Dec 10, 2024, 14:09

Jordi Remon: Alectinib vs crizotinib in 1st line in Asian patients with ALK+ NSCLC

Jordi Remon, Thoracic oncologist at CIOCC Barcelona, shared on X:

“ALESIA Trial: Alectinib vs crizotinib in 1st line in Asian patients with ALK+ NSCLC. OS: NE alectinib vs 81 mo. crozotinib!! Yes with crizotinib. Difference not significant. What would be the CROWN trial (Lorlatinib vs Crizo) if comparator was alectinib?”

Jordi remon